Barclays Starts Coverage on Editas Medicine, Inc. (EDIT) With A Rating Of “Overweight” – First News 24
Key Gazette |
Barclays Starts Coverage on Editas Medicine, Inc. (EDIT) With A Rating Of “Overweight”
First News 24 CRISPR uses a protein-ribonucleic acid (RNA) complex composed of an enzyme, including either Cas9 (CRISPR associated protein 9) or Cpf1 (CRISPR from Prevotella and Francisella 1), bound to a guide RNA molecule designed to recognize a particular … Editas Medicine, Inc. (NASDAQ:EDIT) Closed 6.5% Above Its 50 … |
